Lilly noted in a press release that at 80 weeks, all the doses of retatrutide met the primary and key secondary endpoints for obesity, delivering clinically meaningful weight loss. TRIUMPH-1 highlights the importance of options and the potential for retatrutide to help people across various stages of their obesity journey, Kenneth Custer, PhD, executive vice president and president, Lilly Cardiometabolic Health, said in a press release
The gastric-emptying effect often attenuates over time after dose stabilization
This is what health literacy looks like in clinical practice
Our approach is always GP-led and patient-focused: we advocate for a phased journey that starts with professional consultation, moves through careful symptom tracking, and utilizes structured testing with our How to Test Your Thyroid guide
But of the 13 consensus ratings of the companies in its portfolio, 11 assign the ETF a Buy or Moderate Buy rating, while just two assign it a Hold, and none rate it a Sell
Some people may lose a few pounds in the first week due to a reduced appetite or smaller portion sizes